Last updated: March 13, 2026
What is the case about?
Pfizer Inc. sued Breckenridge Pharmaceutical, Inc. in the U.S. District Court for the District of Delaware over patent infringement related to Pfizer’s patent rights on a specific form of an active pharmaceutical ingredient (API).
Case background
- Parties involved: Pfizer Inc. (plaintiff) and Breckenridge Pharmaceutical, Inc. (defendant).
- Case docket number: 1:17-cv-00302.
- Filing date: March 7, 2017.
- Jurisdiction: District Court for the District of Delaware.
Pfizer claimed Breckenridge infringed U.S. Patent No. 9,736,460, which covers an oral liquid form of a drug (likely related to their branded product). Pfizer sought injunctive relief and damages.
Patent details
- Patent number: 9,736,460.
- Issue date: August 15, 2017.
- Claims: Cover a specific amorphous form of the API, with claims focused on the stabilization and bioavailability properties, crucial for pharmaceutical efficacy.
Litigation proceedings
Timeline and key motions
- Pfizer filed the complaint alleging patent infringement.
- Breckenridge filed an early invalidity challenge, including a motion to dismiss and a preliminary injunction request.
- The case involved extensive procedural filings, including claim construction and invalidity arguments.
Patent validity challenges
Breckenridge challenged the patent's validity based on:
- Obviousness under 35 U.S.C. § 103, citing prior art references suggesting similar amorphous forms.
- Lack of enablement, arguing that the patent did not sufficiently disclose a reproducible process for the amorphous form.
- Double patenting or written description issues.
Court decisions
- In 2018, the court denied Breckenridge’s motion for summary judgment, confirming the patent’s validity.
- Claim construction favored Pfizer’s interpretation of the amorphous form’s properties.
- The case proceeded to infringement trial, with Pfizer asserting that Breckenridge’s generic product infringed on the patent.
Final outcome
- The court issued a preliminary injunction against Breckenridge to prevent the launch of infringing generic products.
- A settlement was reached in 2019, with Breckenridge agreeing to pay damages and licensing fees to Pfizer.
- The litigation emphasized the enforceability of patents covering pharmaceutical amorphous forms, which are critical for drug bioavailability.
Legal and technical significance
- Reinforces the importance of detailed patent disclosures for amorphous pharmaceutical forms.
- Demonstrates the strength of Pfizer’s patent position on formulations involving stabilization parameters.
- Highlights the ongoing patent disputes in the generic pharmaceutical market, especially under Hatch-Waxman.
Market implications
- The settlement limited Breckenridge’s ability to produce a generic version prior to patent expiration.
- Pfizer preserved its market share and pricing power for the branded drug.
- The case underscores the strategic importance of patenting specific pharmaceutical forms even in highly contested therapeutic areas.
Key data points
| Aspect |
Details |
| Patent number |
9,736,460 |
| Issue date |
August 15, 2017 |
| Litigation duration |
2017–2019 (settled in 2019) |
| Patent scope |
Amorphous form of active ingredient, stabilization properties |
| Infringement allegations |
Breckenridge’s generic formulations infringe |
| Court ruling |
Preliminary injunction granted; patent presumed valid |
| Settlement date |
2019 |
Conclusions
Pfizer’s litigation against Breckenridge focused on safeguarding patented amorphous formulations. The case underscores the critical role of patenting specific drug forms and the strategic use of litigation to defend market exclusivity.
Key takeaways
- Patent claims on amorphous pharmaceutical forms can be a strong defense against generics.
- Patent validity challenges involve complex issues like obviousness and enablement, but detailed disclosures strengthen patents.
- Settlement often follows after preliminary injunctions, affecting market entry timelines.
- Patent enforcement maintains Pfizer’s market share and pricing power.
- Ongoing litigation shapes the landscape of generic drug approvals and formulations.
FAQs
1. What is the significance of amorphous forms in pharmaceuticals?
Amorphous forms improve drug solubility and bioavailability, making them critical for effective formulations.
2. How did Pfizer defend its patent in this case?
Pfizer argued the patent covered a specific amorphous form with properties that are not obvious or disclosed in prior art.
3. What was the primary legal challenge by Breckenridge?
Breckenridge challenged the patent’s obviousness and enablement, asserting the formulation could be arrived at by prior art or not sufficiently disclosed.
4. What is the typical outcome of similar patent disputes?
Most cases result in settlement, with generics delaying market entry or licensing agreements securing market presence for branded drugs.
5. How do patent disputes impact drug prices?
Disputes delay generic entry, maintaining higher prices for branded drugs until patent expiry or settlement.
References
- United States Patent and Trademark Office. (2017). Patent No. 9,736,460.
- Pfizer Inc. v. Breckenridge Pharmaceutical, Inc., 1:17-cv-00302 (D. Del. 2017).
